Conflicting Evidence of mRNA Technology Raises Serious Concerns About Rush for Use in New Vax Development
Link in Bio
The U.S. government and pharmaceutical companies are investing a substantial amount to develop new mRNA vaccines for infectious diseases and cancer, fueling a lucrative mRNA platform valued at $136.2 bil…
Keep reading with a 7-day free trial
Subscribe to Dr José Nasser MD PHD Substack to keep reading this post and get 7 days of free access to the full post archives.